Medicare GLP-1 Coverage Drives 700,000 New Senior Users, Lilly Says
Eli Lilly's CEO says 700,000 seniors have started GLP-1 drugs since Medicare coverage launched in July, with 70% choosing Lilly products.
Some 700,000 Medicare-eligible seniors have begun taking GLP-1 medications since the federal program expanded coverage for the drug class in July, Eli Lilly's chief executive said, offering the most concrete figures yet on how the policy shift is reshaping the obesity and diabetes treatment landscape.
Of those new patients, roughly 70% are using Lilly's own GLP-1 therapies, according to the CEO's remarks — a market-share figure that underscores the Indianapolis-based drugmaker's dominant position in a rapidly growing category. Competitor products account for the remaining share of newly covered patients.
Read more Paramount Settles AG Antitrust Suit, Clearing Path for Warner Bros. Deal →
The Medicare expansion marks a significant policy milestone. Prior to the coverage change, many seniors faced substantial out-of-pocket costs for GLP-1 drugs, which can carry list prices of hundreds of dollars per month, limiting access largely to those with private insurance or sufficient personal means.
The data points released by Lilly's chief executive offer early evidence that coverage access is a primary driver of adoption among older Americans, a demographic that stands to benefit significantly from the metabolic and cardiovascular benefits associated with the drug class. Analysts have been closely watching Medicare uptake figures as a signal of long-term demand trajectory for GLP-1 manufacturers.
Continue reading at Business News.
